A study evaluating safety and efficacy of on-demand intramuscular recombinant human complement-C1-inhibitor-protein

Trial Profile

A study evaluating safety and efficacy of on-demand intramuscular recombinant human complement-C1-inhibitor-protein

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Mar 2018 New trial record
    • 05 Mar 2018 Results (n=5) assessing the intramuscular recombinant human complement-C1-inhibitor-protein as an alternatiev to intravenous treatment of hereditary angioedema, were presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 05 Mar 2018 Results presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top